|
| Authors, year | n | Types of shunt | Technique; success rate | Follow-up | Complications | Efficacy; comments |
|
| Mukund et al, 2012 | 7 | Splenorenal-7 | BRTO; 86% | 4 months (mean) | 2 early complications (hepatic and renal dysfunction with bacteremia)-responded to medical management | HE improvement: 100%; retrospective, single-centre study, small sample size, limited follow-up; no endoscopic or long-term imaging data |
| Laleman et al, 2013 | 37 | Splenorenal-20
Paraumbilical-9
Mesocaval-7
Mesorenal 1 | CARTO, PARTO; 100% | 697 days (mean) | 8 early complications-7 mild and 1 capsular bleed
De novo EV-2, EV bleeding-1, nonfatal
Ascites-no significant difference
PVT: 4 (11%; 1 in PV, 3 in one branch) | HE improvement: short-term (100 days): 59.4%
Long-term (2 years): 48.6%;
Retrospective, multicentre study |
| Lynn et al, 2013 | 20 | Splenorenal-12
Rest-other types | CARTO, PARTO; 100% | 12 months (median) | 2 early complications-1 mild, 1 cholangitis
De novo EV-1
Ascites-6 (4 requiring paracentesis) | HE improvement:
Short-term (1–4 months): 100%
Long-term (6–12 months): 92% |
| An et al, 2014 | 17 | Splenorenal-14
Paraumbilical– 3 | CARTO, PARTO; 100% | 19 months (median) | No procedure-related complications
Ascites–3 (mild)
EV: 3, no GIB, no PVT | Recurrence of HE for 2 years:
39.9% (embolized) versus 79.9% (control) |
| Naeshiro et al, 2014 | 14 | Splenorenal-3
Gastrorenal-4
Mesocaval-5
Portocaval-2 | BRTO, CARTO; 92.9% | 27 months (median) | No serious procedure-related complications
EV: worsening at 3 months (21%), worsening at 24 months (29%)
GIB: 14% | HE disappearance in 1–2 weeks: 93% |
| Inoue et al, 2014 | 19 | Splenorenal-19 | BRTO; 100% | 28 months (mean) | No serious procedure-related complications
Ascites: 21% | HE improvement: 100% |
| Philips et al, 2017 | 21 | Splenorenal-17
Mesocaval-7
Rest-other types | CARTO, PARTO,
SSO; 95.2% | 1–9 months | 1 mortality-hemoperitoneum
EV : no significant increase
GIB: 1 nonfatal, ascites: no significant increase | HE improvement:
Short-term follow-up: 71%
Long-term: 23% |
| Philips et al, 2020 | 45 | Splenorenal-25
Mesocaval-4
Paraumbilical-4
Rest-other types | BRTO, CARTO, PARTO,
CAATO; 100% | 18 months | Two study groups-early (first episode of HE) and late (recurrent HE) shunt embolization
Ascites, GIB, recurrence of HE, PVT lower in early shunt embolization group | Recurrence of HE%-4.5 in the early embolization group versus 28.6% in the late embolization group, at 9 months |
|
